Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 26, 2007

Minnesota Partnership Dedicates Genomics Facility

  • As a result of a $21.7 million bonding issue approved by the Minnesota Legislature, a new genomics research facility has been dedicated at the Vincent Stabile Building in Rochester. The three-story addition to the building includes genomic laboratories, facilities for bioinformatics, and conference and meeting rooms that will support ongoing research by the Minnesota Partnership for Biotechnology and Medical Genomics.

    The Minnesota Partnership is a collaborative venture among the Mayo Clinic, University of Minnesota, and State of Minnesota. On December 14, 2006, the University of Minnesota purchased the 12th and 13th floor Partnership research space in the Stabile Building and leased it back to Mayo Clinic.

    "This facility offers Minnesota Partnership researchers the laboratory support and technology needed to speed research aimed at major diseases affecting the people of the state," says Glenn Forbes, M.D., CEO of Mayo Clinic, Rochester.

    The facility will house approximately 300 researchers. "The kind of space we are providing to researchers in the Stabile Building will help us to attract top talent and research dollars for the Partnership and it will serve as a catalyst for other bioscience development in Minnesota," says Frank Cerra, senior vp for Health Sciences, University of Minnesota.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »